 Cardiff Oncology, Inc. Nasdaq: CRDF, a San Diego, CA-based clinical-stage oncology therapeutics company, has entered into a securities purchase agreement, which includes common stock, non-voting Series E preferred stock and warrants for aggregate gross proceeds of 13.5m 